A Phase 3, Randomized, Controlled Study of Prophylactic and On-demand Treatment of cTTP With BAX 930 (rADAMTS13)

Investigator: Lawrence Rice, MD

Study Coordinator: Juan Morales Viera

Status: Enrolling

ClinicalTrials.gov Number: NCT03393975

Phone: 786.803.2333

Protocol Number: Pro00017827


To purpose of this study is to assess safety and efficacy of BAX 930 in the prevention and treatment of acute episodes of thrombotic thrombocytopenic purpura (TTP) in subjects with severe hereditary deficiency of ADAMTS13 (cTTP; defined as plasma ADAMTS13 <10%, as measured by the fluorescent resonance energy transfer-VWF73 [FRETS] assay)
More to Explore